Eisai and Biogen Receive US FDA Approval for Alzheimer’s Drug and Seek Full Approval
Jan 7 (Reuters) – The U.S. Food and Drug Administration on Friday approved Alzheimer’s disease drug lecanemab, developed by Eisai Co Ltd (4523.T) and Biogen Inc (BIIB.O) for patients in the early stages of mind sickness. Eisai and Biogen said on Saturday that the Japanese drugmaker had sought full FDA approval for the drug. The …
Eisai and Biogen Receive US FDA Approval for Alzheimer’s Drug and Seek Full Approval Read More »